BMO Capital analyst Gary Nachman maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Outperform and raises the price target from $185 to $188.
Bitcoin-Miner CleanSpark’s Stock Climbs After Strong Q2 Revenue, 2 New Mining Locations
CleanSpark said quarterly revenue clocked in at $111.8 million which beat the analyst consensus estimate of $102.574 million by 8.99% and represents a 162.77% increase in revenue from the same period last year. The company also reported quarterly GAAP earnings of 58 per share.
